胸腺肽类免疫调节药物在新型冠状病毒肺炎中合理使用与药学监护  

Rational Use and Pharmaceutical Care of Thymosin Immunomodulators for Novel Coronavirus Pneumonia

作　　者：刘心霞[1] 申平鑫 杜姗[1] 杨勇[1] 舒永全[1] 边原[1] 童荣生[1] 闫峻峰[1] 何林[1] 龙恩武[1] 陈岷[1] LIU Xinxia;SHEN Pingxin;DU Shan;YANG Yong;SHU Yongquan;BIAN Yuan;TONG Rongsheng;YAN Junfeng;HE Lin;LONG Enwu;CHEN Min(Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Personalized Drug Therapy Key Laboratory of Sichuan Province,Chengdu,Sichuan 610072,China;Department of Pharmacy,People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture,Sichuan Aba 624000,China)

机构地区：[1]四川省医学科学院·四川省人民医院,电子科技大学附属医院药学部,个体化药物治疗四川省重点实验室,成都610072 [2]阿坝藏族羌族自治州人民医院药剂科,四川阿坝624000

出　　处：《医药导报》2020年第4期451-458,共8页Herald of Medicine

基　　金：国家临床重点专科建设资助项目(30305030698);四川省卫生健康委员会科研课题资助项目(19PJ269);四川省人民医院博士基金课题资助项目(2015BS04)。

摘　　要：有效的机体免疫应答与新型冠状病毒肺炎的预后有重要关系,免疫系统在清除细胞内病毒感染中发挥重要作用。胸腺肽类免疫调节药物能增强机体免疫功能。该文根据现有证据,对临床常用胸腺肽类药物的来源、区别、及其在不同人群中的免疫调节作用和在病毒感染治疗中的应用进行归纳总结,探讨其在新型冠状病毒感染预防和治疗中的作用,并对药物选择和药学监护提出建议,以期为新型冠状病毒肺炎相关临床决策提供参考,提高临床防治效果。The prognosis of novel coronavirus pneumonia is closely related to host's immune response.Immunity system plays a vital role in controlling and eliminating virus infections.Thymosin immunomodulators can enhance the body's cellular immune function.Based on existing evidences,this paper reviews the sources and differences of thymosin drugs,of which the immunomodulatory effects in different populations and application in viral infection are also summarized.In addition,we discuss the roles of thymosin drugs in the prevention and treatment of new coronavirus infections,and put forward suggestions for drug selection and pharmaceutical care,in order to provide reference for clinical decision-making related to new coronavirus pneumonia and improve its prevention and treatment effects.

关 键 词：胸腺肽类 免疫调节药物 新型冠状病毒肺炎 COVID-19 合理使用 药学监护 

分 类 号：R978.7[医药卫生—药品] R511[医药卫生—药学]